GlassScriptPhysician profile
Mark Rosenblum
NPI 1003809310
$11,177.47
in general payments reported to CMS, 2019-2025
51 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,616 · 2020: $1,096 · 2021: $1,865 · 2022: $1,327 · 2023: $1,662 · 2024: $2,214 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,162 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.54 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,661.90 | 2021-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $916.03 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $915.58 | 2019-2025 | Erleada, Akeega |
| Neotract INC. | $804.30 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $516.10 | 2019-2025 | Provenge |
| Myriad Genetic Laboratories, INC. | $488.12 | 2021-2025 | Prolaris |
| Progenics Pharmaceuticals, INC. | $444.39 | 2021-2025 | Pylarify |
| Pfizer INC. | $426.43 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $424.81 | 2023-2025 | Orgovyx, Gemtesa |
| Urogen Pharma, INC. | $404.73 | 2021-2024 | Jelmyto |
| Endo Pharmaceuticals INC. | $363.96 | 2019-2024 | Edex, Xiaflex, Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $353.66 | 2019-2024 | |
| Abbvie INC. | $314.74 | 2019-2025 | Botox |
| Antares Pharma, INC. | $262.92 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $248.50 | 2021-2025 | Keytruda, Lynparza, Welireg |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rosenblum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.